Kutlu Y - Search Results

1

Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer.

Goktas Aydin S, Bilici A, Calis E, Kutlu Y, Hamdard J, Muglu H, Fatih Olmez O, Karci E, Acikgoz O. Goktas Aydin S, et al. Among authors: kutlu y. Int Immunopharmacol. 2023 Nov;124(Pt B):110947. doi: 10.1016/j.intimp.2023.110947. Epub 2023 Sep 22. Int Immunopharmacol. 2023. PMID: 37742369

2

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.

Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A. Gürbüz M, et al. Among authors: kutlu y. J Cancer Res Clin Oncol. 2022 Dec;148(12):3547-3555. doi: 10.1007/s00432-022-04087-x. Epub 2022 Jun 11. J Cancer Res Clin Oncol. 2022. PMID: 35689097

3

The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer.

Goktas Aydin S, Bilici A, Olmez OF, Oven BB, Acikgoz O, Cakir T, Basim P, Cakir A, Kutlu Y, Hamdard J. Goktas Aydin S, et al. Among authors: kutlu y. Breast Care (Basel). 2022 Oct;17(5):470-479. doi: 10.1159/000524446. Epub 2022 May 3. Breast Care (Basel). 2022. PMID: 36684400 Free PMC article.

4

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.

Kutlu Y, Aydin SG, Bilici A, Oven BB, Olmez OF, Acikgoz O, Hamdard J. Kutlu Y, et al. Medicine (Baltimore). 2023 Apr 14;102(15):e33432. doi: 10.1097/MD.0000000000033432. Medicine (Baltimore). 2023. PMID: 37058061 Free PMC article.

5

The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.

Aydin SG, Olmez OF, Selvi O, Geredeli C, Ozden F, Bilici A, Acikgoz O, Karci E, Kutlu Y, Hamdard J, Aydin A. Aydin SG, et al. Among authors: kutlu y. J Gastrointest Cancer. 2024 Mar;55(1):227-236. doi: 10.1007/s12029-023-00953-0. Epub 2023 Jun 22. J Gastrointest Cancer. 2024. PMID: 37347353

6

Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Goktas Aydin S, Kutlu Y, Muglu H, Aydin A, Acikgoz O, Hamdard J, Karci E, Bilici A, Olmez OF, Yildiz O. Goktas Aydin S, et al. Among authors: kutlu y. Cancer Chemother Pharmacol. 2024 Jan;93(1):71-78. doi: 10.1007/s00280-023-04592-x. Epub 2023 Sep 29. Cancer Chemother Pharmacol. 2024. PMID: 37773537

7

Integrated FDG-PET/CT contribution over cross-sectional imaging in recurrence or progression of pancreaticobiliary neoplasms.

Karaalioglu B, Cakir T, Kutlu Y, Seker M, Bilici A. Karaalioglu B, et al. Among authors: kutlu y. Abdom Radiol (NY). 2024 Jan;49(1):131-140. doi: 10.1007/s00261-023-04109-3. Epub 2023 Nov 22. Abdom Radiol (NY). 2024. PMID: 37991533

8

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.

Yıldırım HÇ, Kutlu Y, Mutlu E, Aykan MB, Korkmaz M, Yalçın S, Şakalar T, Celayir ÖM, Kayıkçıoğlu E, Aslan F, Hafızoğlu E, Altıntaş YE, Keskinkılıç M, Chalabiyev E, Çelebi A, Dursun B, Kapar C, Özen M, Acar Ö, Dülgar Ö, Kut E, Biter S, Kus F, Almuradova E, Erdoğan AP, Saray S, Güven DC, Şimşek ET, Üskent N, Kemal Y, Çakar B, Açıkgöz Ö, Kılıçkap S, Aksoy S. Yıldırım HÇ, et al. Among authors: kutlu y. Int J Clin Oncol. 2024 Mar;29(3):258-265. doi: 10.1007/s10147-023-02460-5. Epub 2024 Feb 4. Int J Clin Oncol. 2024. PMID: 38310597

9

Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer.

Kutlu Y, Cekin R, Aydin SG, Shbair ATM, Bilici A, Arici S, Oven BB, Acikgoz O, Ozcan E, Olmez OF, Cakir A, Seker M. Kutlu Y, et al. Curr Probl Cancer. 2024 Jun;50:101102. doi: 10.1016/j.currproblcancer.2024.101102. Epub 2024 May 11. Curr Probl Cancer. 2024. PMID: 38735211

10

Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience.

Hamdard J, Bilici A, Sakin A, Kahraman S, Yasin AI, Kalaci E, Gokmen I, Acikgoz O, Kutlu Y, Sendur MAN, Olmez OF, Seker M. Hamdard J, et al. Among authors: kutlu y. J Chemother. 2024 May 27:1-10. doi: 10.1080/1120009X.2024.2358458. Online ahead of print. J Chemother. 2024. PMID: 38803194

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters